Pharmacokinetics of piperaquine after single and multiple oral administrations in healthy volunteers

被引:17
作者
Liu, Changhui [1 ]
Zhang, Rong [1 ]
Hong, Xin [1 ]
Huang, Tianlai [1 ]
Mi, Suiqing [1 ]
Wang, Ningsheng [1 ]
机构
[1] Guangzhou Univ Chinese Med, Inst Clin Pharmacol, Guangzhou 510405, Guangdong, Peoples R China
来源
YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN | 2007年 / 127卷 / 10期
关键词
piperaquine; pharmacokinetics; HPLC-UV;
D O I
10.1248/yakushi.127.1709
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The aim of this work was to study the pharmaco kinetics of piperaquine in healthy volunteers. Healthy volunteers received piperaquine and tablets of Artekin by oral administration. The plasma samples were analyzed for piperaquine by liquid-liquid extraction and determined by HPLC-UV. The results demonstrated that the plasma drug concentration-time curves of single and multiple dose of piperaquine were fitted to a two-compartment open model. The pharmacokinetics parameters of piperaquine alone in a single dose were: t(1/2(beta)) (317.2-/+126.6)h, AUC(0 ->infinity)=(44293-/+ 12636)hXng/ml, V-d=(9490.9-/+2161.9)ml/kg, and Cl=(22.83-/+9.83)ml/h/kg. In Artekin in a single dose these parameters were: t(1/2(beta)) (302.8-/+180.7)h, AUC(0 ->infinity) = (46419-/+13670)hXng/ml, V-d=(10188.6-/+ 3520.3)ml/kg, and Cl= (25.48-/+10.89)ml/h/kg, while in Artekin in multiple doses they were: t(1/2(beta))= (298.9-/+ 101.9)h,AUC(0 ->infinity-)= (227692-/+56294)hxng/ml,V-d=(5031.5-/+1097.8)ml/kg, Cl=(11.91-/+3.046)ml/h/kg, respectively. The absorption and distribution of piperaquine were quick while the elimination was quite slow. There were significant differences in the pharmacokinetics parameters of piperaquine in Artekin between a single dose and multiple doses (p < 0.001), suggesting that piperaquine might accumulate in vivo and that attention should be given to its possible adverse drug reactions in clinical treatment.
引用
收藏
页码:1709 / 1714
页数:6
相关论文
共 11 条
  • [1] CHEN L, 1982, CHINESE MED J-PEKING, V95, P281
  • [2] CHEN Q, 1979, PHARM IND, V8, P19
  • [3] DENG M, 2004, CHINESE J CLIN PHARM, V20, P67
  • [4] Hung TY, 2004, BRIT J CLIN PHARMACO, V57, P253, DOI [10.1046/j.1365-2125.2003.02004.x, 10.1111/j.1365-2125.2003.02004.x]
  • [5] Novel bisquinoline antimalarials - Synthesis, antimalarial activity, and inhibition of haem polymerisation
    Raynes, K
    Foley, M
    Tilley, L
    Deady, LW
    [J]. BIOCHEMICAL PHARMACOLOGY, 1996, 52 (04) : 551 - 559
  • [6] Pharmacokinetics of piperaquine after repeated oral administration of the antimalarial combination CV8 in 12 healthy male subjects
    Roshammar, D
    Hai, TN
    Hietala, SF
    Huong, NV
    Ashton, M
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 62 (05) : 335 - 341
  • [7] SUNDERLAND B, 2002, M ANT DRUG DEV SHANG, P41
  • [8] BISQUINOLINES .1. N,N-BIS(7-CHLOROQUINOLIN-4-YL)ALKANEDIAMINES WITH POTENTIAL AGAINST CHLOROQUINE-RESISTANT MALARIA
    VENNERSTROM, JL
    ELLIS, WY
    AGER, AL
    ANDERSEN, SL
    GERENA, L
    MILHOUS, WK
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1992, 35 (11) : 2129 - 2134
  • [9] Strategies for the prevention of antimalarial drug resistance: Rationale for combination chemotherapy for malaria
    White, NJ
    Olliaro, PL
    [J]. PARASITOLOGY TODAY, 1996, 12 (10): : 399 - 401
  • [10] WHITE NJ, 1999, PARASSITOLOGIA, V41, P310